Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Moderna, Inc. (MRNA) Price & Performance

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Moderna, Inc. — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.28 (market cap $40.01B), while Moderna, Inc. trades at $197.5 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.14% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and Moderna, Inc. for 59 Days on average.

HLNMRNA
Market Cap
$40.01B$78.65B
Volume
19,985,93537,373,437
Sector
HealthHealth
52-Week High
$11.27$203.46
52-Week Low
$8.70$22.36
Typical Hold Time
0 Days59 Days
Enterprise Value
$49.79B$74.80B
Dividend Yield
2.14%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

No Aura AI signal available yet.

Moderna, Inc.

Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.

While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLN
100% Buy0% Sell
Avg holding period · 0 Days
MRNA
29% Buy71% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →